Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BI 2536 + Pemetrexed in Previously Treated NSCLC
NCT02211833Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Oct 2006
- Primary completion
- Feb 2009
- Modality
- Small Molecules
01
Overview
Phase 1, open-label, single-arm trial of BI-2536 in non-small cell lung cancer (NSCLC), sponsored by Boehringer Ingelheim. Primary endpoints: Maximum Tolerated Dose up to 3 weeks and Number of patients with adverse events up to 20 weeks. Started Oct 2006; status: completed.
02
Drugs
BI-2536
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT02211833.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02211833.